- Conditions
- Immune Thrombocytopenia
- Interventions
- Avatrombopag, Placebo
- Drug
- Lead sponsor
- Sobi, Inc.
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Long Beach, California • Orange, California + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Idiopathic Thrombocytopenia Purpura
- Interventions
- E5501, Drug: E5501
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Thrombocytopenia Associated With Liver Disease
- Interventions
- avatrombopag (lower baseline platelet count), placebo (lower baseline platelet count), avatrombopag (higher baseline platelet count), placebo (higher baseline platelet count)
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 21
- States / cities
- Lancaster, California • Long Beach, California • Los Angeles, California + 18 more
- Conditions
- Immune Thrombocytopenia
- Interventions
- Avatrombopag Oral Tablet
- Drug
- Lead sponsor
- Sobi, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • Whittier, California • Washington D.C., District of Columbia + 17 more
- Conditions
- Thrombocytopenia Related to Chronic Liver Disease
- Interventions
- Avatrombopag, Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Healthy Subjects
- Interventions
- E5501
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Thrombocytopenia Associated With Liver Disease
- Interventions
- avatrombopag (lower baseline platelet count), placebo (lower baseline platelet count), avatrombopag (higher baseline platelet count), placebo (higher baseline platelet count)
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 20 more
- Conditions
- Chronic Idiopathic Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Idiopathic
- Interventions
- Placebo, Avatrombopag tablets
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 25
- States / cities
- Anaheim, California • Bakersfield, California • Concord, California + 21 more
- Conditions
- Idiopathic Thrombocytopenic Purpura
- Interventions
- Blinded (placebo), Open Label (Avatrombopag tablets), Blinded (Avatrombopoag tablets)
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 12
- States / cities
- Anaheim, California • Bakersfield, California • Manchester, Connecticut + 8 more
- Conditions
- Chemotherapy-induced Thrombocytopenia
- Interventions
- Avatrombopag, Placebo Oral Tablet
- Drug
- Lead sponsor
- Sobi, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 14
- States / cities
- Anaheim, California • Bakersfield, California • Riverside, California + 11 more
- Conditions
- Healthy Volunteers
- Interventions
- Avatrombopag maleate 40 mg
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Gastrointestinal Cancer, Gastrointestinal Neoplasms, Chemotherapy-Induced Thrombocytopenia
- Interventions
- Avatrombopag, Matching Placebo
- Drug
- Lead sponsor
- Hanny Al-Samkari, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 4
- States / cities
- Miami, Florida • Boston, Massachusetts • Portland, Oregon + 1 more